Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial

BACKGROUND: Sunitinib is a tyrosine kinase inhibitor approved in the first-line metastatic renal cell carcinoma (MRCC) setting at the dose of 50 mg daily for 4 weeks followed by a pause of 2 weeks. Due to toxicity, this standard schedule (50 mg daily 4/2) can induce up to 50% of sunitinib dose modif...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouillet, Guillaume, Paillard, Marie-Justine, Maurina, Tristan, Vernerey, Dewi, Nguyen Tan Hon, Thierry, Almotlak, Hamadi, Stein, Ulrich, Calcagno, Fabien, Berthod, Diane, Robert, Elise, Meurisse, Aurelia, Thiery-Vuillemin, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898055/
https://www.ncbi.nlm.nih.gov/pubmed/29650037
http://dx.doi.org/10.1186/s13063-018-2613-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898055/
https://www.ncbi.nlm.nih.gov/pubmed/29650037
http://dx.doi.org/10.1186/s13063-018-2613-8

Ejemplares similares